Recruiting Amyloidosis Studies in Atlanta
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that accumulates in different orga...
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL)....
About Amyloidosis Clinical Trials in Atlanta
Amyloidosis is a group of diseases in which abnormal proteins (amyloids) build up in organs and tissues, impairing their function. Types include AL, AA, and ATTR amyloidosis. Treatment depends on the type and may include chemotherapy, organ transplant, or targeted therapies.
There are currently 2 amyloidosis clinical trials recruiting participants in Atlanta, GA. These studies are seeking a combined 622 participants. Research is being sponsored by Eidos Therapeutics, a BridgeBio company, Nexcella Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Amyloidosis Clinical Trials in Atlanta — FAQ
Are there amyloidosis clinical trials in Atlanta?
Yes, there are 2 amyloidosis clinical trials currently recruiting in Atlanta, GA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Atlanta?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Atlanta research site will contact you about next steps.
Are clinical trials in Atlanta free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Atlanta studies also compensate for your time and travel.
What amyloidosis treatments are being tested?
The 2 active trials in Atlanta are testing new therapies including novel drugs, biologics, and treatment approaches for amyloidosis.
Data updated March 2, 2026 from ClinicalTrials.gov